Introduction
============

Essential hypertension is the most prevalent cardiovascular disease in the world, and a major public health issue. Its prevalence is increasing in the adult population, and is estimated to be 30% in developed countries ([@b1]; [@b14]). Arterial hypertension, in which insulin resistance is common, is strongly associated with type 2 diabetes. Diabetes mellitus is increasing rapidly worldwide, and since many patients with hypertension develop diabetes, this combination of risk factors will account for a large proportion of cardiovascular morbidity and mortality ([@b16]; [@b36]).

International Guidelines for the Management of Hypertension have emphasized that blood pressure (BP)-lowering therapy can reduce macrovascular disease for diabetic patients which may be more significant than blood glucose control ([@b37]). Results from different studies ([@b15]; [@b40]; [@b41]; [@b42]) have demonstrated that aggressive lowering of diastolic BP (DPB) in diabetic patients was accompanied by reductions of macrovascular and microvascular events. In addition, the aggressive antihypertensive treatment of diabetic patients with systolic hypertension has been favored in some studies ([@b35]; [@b3]; [@b7]).

Pharmacological agents recommended as initial therapy for diabetic patients include diuretics, β-blockers, angiotensin converting enzyme (ACE) inhibitors, calcium channel blockers, and angiotensin II blocker receptors (ARBs) ([@b13]; [@b8]). The choice of antihypertensive drug regimen in diabetic subjects is important for several reasons: they are susceptible to suffer metabolic decompensation, and the diabetic state may alter the pharmacokinetics of several cardiovascular drugs ([@b33]). In this way, captopril was found superior to a diuretic/β-blocker antihypertensive treatment in diabetic patients, especially in those with metabolic decompensation ([@b27]). Consequently, dosage requirements established for non-diabetic patients, when applied to the patient with diabetes, may potentially result in either therapeutic failure or undesirable adverse effects. Some epidemiological and clinical studies suggested a causal link between the use of thiazide diuretics and the subsequent development of type 2 diabetes ([@b4]; [@b29]), and β-blockers are not specifically indicated in diabetic patients ([@b34]). ACE inhibitors ([@b39]; [@b32]; [@b5]; [@b28]; [@b29]; [@b34]) and calcium channel antagonists ([@b39]; [@b29]; [@b34]) have little or no significant effects on plasma glucose and insulin levels in patients with and without diabetes.

ARBs have beneficial renal effects in patients with diabetes and nephropathy ([@b6]; [@b19]; [@b30]; [@b21]). A recent study demonstrated that a subset of angiotensin receptor antagonists (ARAs) induces peroxisome proliferators-acti-vated receptor (PPARγ), providing a potential mechanism for their insulin-sensitizing/antidiabetic effects ([@b34]) and an opportunity for the prevention and treatment of diabetes and cardiovascular disease in high-risk populations ([@b31]). Among the ARBs, candesartan cilexetil (CC) is a potent, highly selective, angiotensin II type 1 (AT1) blocker receptor. Due to tight binding to and slow dissociation from the receptor, CC provides a strong, dose-dependent, and long-lasting antihypertensive effect. CC does not affect glucose homeostasis or the serum lipid profile ([@b38]), and is effective in reducing BP and microalbuminuria ([@b25]) in hypertensive patients with type 2 diabetes. Five randomized double-blind studies ([@b9]; [@b17]; [@b2]; Olivier JP, pers comm; Baguet JP, pers comm) demonstrated the efficacy of CC (8--16 mg) in controlling hypertensive patients. Whether this efficacy is similar in diabetic and non-diabetic patients is not yet established. The aim of this study was to analyze the effect of CC on BP in these two populations by pooling data from five randomized double-blind clinical trials ([@b9]; [@b17]; [@b2]; Olivier JP, pers comm; Baguet JP, pers comm).

Materials and methods
=====================

Study population
----------------

This was a retrospective data meta-analysis of five randomized double-blind studies ([@b38]; [@b25]; [@b17]; Baguet JP, pers comm; Olivier JP, pers comm) evaluating the efficacy of CC (8--16 mg). These five studies had a similar design: 2-to 4-week placebo wash out period, followed by 4-to 6-week double-blind period where patients received the active drug once daily. After this period, if BP was not normalized (SBP or DBP ≥140/90 mmHg or ≥130/80 mmHg in diabetes patients) the treatment could be doubled during another 4- to 6-week period. Efficacy was analyzed at V1 (after the first CC period treatment) and at V2 (after the second period treatment). A total of 702 patients treated by CC were included in this analysis.

Statistical analysis
--------------------

All statistical analysis was undertaken using a Number Cruncher Statistical System (NCSS 2000, Kaysville, Utah, USA). Quantitative variables were expressed as mean ± SD, minimum and upper values, and were compared using a Student's t-test; a Wilcoxon test was performed if the data were not normally distributed. Qualitative variables were expressed as absolute number and percentage values, and were analyzed using a Chi-square test.

Mean pressure values were compared before and after CC treatment in each group, and between groups (diabetic and non-diabetic patients) using a t-test. Final blood pressure (V1 and V2) comparison between diabetic and non-diabetic group was performed by a covariance analysis with and adjustment to the initial BP values and weight. P \< 0.05 was considered statistically significant.

Results
=======

Patients
--------

The patient characteristics are presented in [Table 1](#tbl1){ref-type="table"}. This analysis included 702 hypertensive patients composed of two sub-groups: 153 of diabetic patients (21.8%) and 549 of non-diabetic patients (78.2%). Patients were principally men (57%), with 60 ± 11 years of age. Diabetic patients had higher weight values than non-diabetic patients. At baseline, systolic and diastolic blood pressure values were significantly higher in non-diabetic patients compared with diabetic ([Table 1](#tbl1){ref-type="table"}).

###### 

Baseline characteristics of patients

                         Diabetic n = 153   Non-diabetic n = 549   Total n = 702   P values
  ---------------------- ------------------ ---------------------- --------------- ----------
  Age, years             60 ± 9             60 ± 12                60 ± 11         NS
  Male, n (%)            88 (57.5)          309 (56.3)             397 (56.6)      NS
  Weight, kg             84 ± 17            75 ± 15                77 ± 15         \<0.001
  Height, cm             165 ± 8            167 ± 9                167 ± 9         NS
  Systolic BP, mmHg      158 ± 13           160 ± 13               160 ± 13        0.03
  Diastolic BP, mmHg     92 ± 9             95 ± 10                94 ± 10         \<0.001
  Pulse pressure, mmHg   66 ± 13            65 ± 14                65 ± 14         NS
  Heart rate, bpm        75 ± 10            73 ± 10                73 ± 10         NS

Results are given as mean ± SD.

Antihypertensive effect of candesartan cilexetil
------------------------------------------------

### Blood pressure reduction in overall population

Changes of SBP, DBP, and pulse pressure (PP) values after CC treatment for all patients are shown in [Figure 1](#fig1){ref-type="fig"}. Blood pressure values showed a significant decrease at V1 and V2 following CC 8--16 mg treatments. In the global population significant reductions at V1 (p \< 0.001) and V2 (p \< 0.001) were found for SBP, DBP, and PP ([Figure 1a](#fig1){ref-type="fig"}). The most important change occurred between baseline and V1 (SBP/DBP/PP: −14/--9/--5 mmHg), but the BP values continued to decrease up to V2 (SBP/DBP/PP: −18/--10/--7 mmHg), reaching final BP values of 141/83/58 mmHg for SBP, DBP, and PP respectively ([Figure 1a](#fig1){ref-type="fig"}). Mean changes in heart rate were not significant at V1 (--0.2 bpm) or at V2 (--1.1 bpm), reaching a final value of 72 bpm.
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### Blood pressure reduction in diabetic patients

In diabetic patients, significant reductions at V1 (p \< 0.001) and V2 (p \< 0.001) were found for SBP, DBP, and PP ([Figure 1b](#fig1){ref-type="fig"}). The most important change occurred between baseline and V1 (SBP/DBP/PP: −14/--9/--5 mmHg), but the BP values continued to decrease up to V2 (SBP/DBP/PP: −21/--11/--10 mmHg), reaching final BP values of 137/82/55 mmHg for SBP, DBP, and PP respectively ([Figure 1b](#fig1){ref-type="fig"}). Mean changes in heart rate were not significant at V1 (--0.3 bpm) or at V2 (--1.3 bpm), reaching a final value of 73 bpm.

### Blood pressure reduction in non-diabetic patients

In non-diabetic patients, significant reductions at V1 (p \< 0.001) and V2 (p \< 0.001) were found for SBP, DBP, and PP ([Figure 1c](#fig1){ref-type="fig"}), with the most important change between baseline and V1 (SBP/DBP/PP: −14/--9/--5 mmHg), and a less pronounced decrease up to V2 (SBP/DBP/PP: −17/--11/--7 mmHg), reaching final BP values of 143/84/59 mmHg for SBP, DBP, and PP respectively ([Figure 1c](#fig1){ref-type="fig"}). Mean changes in heart rate were not significant at V1 (--0.2 bpm) or at V2 (--1 bpm), reaching a final value of 72 bpm.

### Comparison of antihypertensive effect of CC in diabetic and non-diabetic patients

[Table 2](#tbl2){ref-type="table"} compares mean changes of BP and heart rate values between diabetic and non-diabetic patients. At V1, the reductions observed in BP and heart rate values compared with baseline were similar for both diabetic and non-diabetic patients. At V2, the reductions observed in BP values compared with the baseline were more important in diabetic patients for SBP, DBP and PP values (p \< 0.001) than in non-diabetic patients ([Table 2](#tbl2){ref-type="table"}). The mean changes in heart rate were not statistically significant between diabetic and non-diabetic patients.

###### 

Blood pressure changes in diabetic and non-diabetic hypertensive patients

                                       Diabetic n = 153   Non-diabetic n = 549                         
  ------------------------------------ ------------------ ---------------------- ---------- ---------- ---------
  V1[a](#tf2-1){ref-type="table-fn"}                                                                   
  Systolic BP, mmHg                    143 ± 17           −14 ± 14               146 ± 16   −14 ± 15   NS
  Diastolic BP, mmHg                   84 ± 10            −9 ± 10                86 ± 10    −9 ± 10    NS
  Pulse pressure, mmHg                 59 ± 12            −5 ± 11                60 ± 13    −10 ± 9    NS
  Heart Rate, bpm                      74 ± 9             −0.3 ± 7               73 ± 9     −0.2 ± 9   NS
  V2[b](#tf2-2){ref-type="table-fn"}                                                                   
  Systolic BP, mmHg                    137 ± 15           −21 ± 15               143 ± 15   −17 ± 14   \<0.001
  Diastolic BP, mmHg                   82 ± 9             −11 ± 9                84 ± 10    −10 ± 10   0.034
  Pulse pressure, mmHg                 55 ± 10            −10 ± 13               60 ± 13    −7 ± 13    \<0.001
  Heart rate, bpm                      73 ± 9             −1.3 ± 7               72 ± 9     −1 ± 9     NS

Mean change values were obtained comparing with the baseline.

V1:4- to 6-week period of treatment with CC 8 mg once daily.

V2: 8- to 12-week period of treatment with 8--16 mg once daily.

Discussion
==========

Previous studies have shown that antihypertensive agents may exert different effects on glycemic control. In general, ACE inhibitors, ARAs, and calcium channel blockers seem to have neutral or beneficial effects, whereas β-blockers and thiazide diuretics tend to worsen insulin resistance for glycemic control ([@b4]; [@b29]; [@b34]). However, studies have shown conflicting results, even between agents within the same classes ([@b29]). Rather than using surrogate blood pressure end points, with different antihypertensive agents, it may be more clinically relevant to examine the effect of the same treatment on controlling hypertensive diabetic and non-diabetic patients. Several trials have been conducted in diabetic patients comparing two or more drugs ([@b10]; [@b43]; HOPE 2000; [@b20], [@b21]; [@b25]; [@b27]; [@b26]), or an active drug against placebo ([@b35]; [@b38]; [@b23]) but only few studies have evaluated blood pressure lowering using one drug in the same study comparing the effect in diabetic and non-diabetic patients ([@b18]; [@b33]; [@b12]).

The present analysis pooled data of five randomized double-blind clinical trials ([@b9]; [@b17]; [@b2]; Olivier JP, pers comm; Baguet JP, pers comm) with the objective of analyzing the effect of CC on diabetic and non-diabetic patients. The antihypertensive effect of CC 8--16 mg was observed by BP reduction achieved by 12 weeks in all patients treated.

BP values in diabetic hypertensive patients are usually higher than in non-diabetic patients despite the use of larger number of drugs ([@b10]; [@b18]; [@b43]; HOPE 2000; [@b20], [@b21]; [@b6]; [@b19]; [@b27]; [@b30]; [@b12]; [@b23]; [@b26]). Indeed, treatment is accompanied by large BP reductions, but while achieved DBP is almost invariably well below 90 mmHg and even 80 mmHg, the concomitant SBP remained above 140 mmHg ([@b6]; [@b19]; [@b30]; [@b21]). Thus, in hypertensive diabetic patients treated with irbesartan 300 mg or amlodipine 10 mg, the final average SBP/DBP values were 140/77 mmHg and 141/77 mmHg respectively ([@b19]). Irbesartan 150 mg and irbesartan 300 mg administrated to hypertensive diabetic patients with nephropathy gave final SBP/DBP values of 143/83 and 141/83 mmHg, respectively ([@b30]). Hypertensive diabetic patients treated by losartan achieved mean SBP/DBP final values of 140/74 mmHg vs placebo ([@b6]), and of 146/79 mmHg vs atenolol ([@b21]).

In a previous study, CC 8--16 mg lowered SBP/DBP values to 149/89 mmHg compared with 151/90 with placebo ([@b38]). In the present analysis, a more important reduction in mean SBP, DBP, and PP values was observed in diabetic (137/82/55 mmHg) compared with nondiabetic patients (143/84/59 mmHg).

In spite of a good response to CC in BP lowering, the recommendations to lower SBP in diabetic patients to values below 130 mmHg were not totally achieved. The difference in the BP response between diabetic and non-diabetic patients may partly be explained by a physiological mechanisms differently acting in diabetic and non diabetic patients.

Several randomized clinical trials suggested that the inhibition of the renin-angiotensin (RA) system reduces the risk of new onset of type 2 diabetes mellitus (T2DM) in patients with arterial hypertension ([@b29]; [@b34]) or with congestive heart failure ([@b29]). Considering the pandemic of T2DM, such a pharmacological approach deserves further attention among the strategies aiming at preventing the disease. This preventive effect of the RA inhibition should involve the intimate mechanisms of the complex pathophysiology of T2DM. A Japanese study suggested that hypoadiponectinemia is related to insulin resistance in essential hypertension ([@b11]). It also showed that treatment with temocarpil or candesartan significantly decreases blood pressure and increased insulin-mediated glucose disposal and plasma adiponectin concentrations ([@b11]). These observations require further investigation.

Another possible mode of action has been hypothesized for ARBs. A recent study ([@b24]) demonstrated that a subset of ARAs induces PPAR-γ activity by interaction with the PPAR-γ ligand binding domain. ARAs with PPAR-γ activating properties at low (telmisartan), medium (irbesartan), and very high concentrations (losartan) as well as a non-activating ARA (eposartan) have been identified. The authors concluded that molecules that can simultaneously block the ATII receptor and activate PPAR-γ have the potential to treat both hemodynamic and biochemical features.

CC has been useful in treating hypertensive patients who have experienced side-effects with other antihypertensive agents. Its good tolerability has been reported and favorable effects on target organ damage, morbidity, and mortality were achieved in long-term studies ([@b23]). The lower rate of new-onset diabetes mellitus reported in the CC group compared with the control group found in SCOPE is of the same magnitude as that observed in the other ARB losartantreated group compared with the β-blocker treated group in the LIFE study ([@b21]). A more favorable metabolic profile and a lower risk of developing diabetes in hypertensive patients treated with CC 16 mg was also described in the ALPINE study ([@b22]).

CC has potential as initial treatment of hypertension and, as shown in the present analysis, CC was effective in diabetic as well as in non-diabetic patients, and furthermore, with a significant SBP, DBP, and PP lowering in diabetic patients. CC merits further investigation in diabetic patients.
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